A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

NCT02018861 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Malignancies

Interventions

DRUG: Parsaclisib
DRUG: Itacitinib
DRUG: Rituximab
DRUG: Ifosfamide
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Incyte Corporation